D-0109-2017 Class III Terminated

Recalled by Teva Pharmaceuticals USA — North Wales, PA

FDA drug recall D-0109-2017 was initiated by Teva Pharmaceuticals USA on Sep 22, 2016 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing. The recall status is terminated (terminated May 5, 2017). Affected quantity: 32,015 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 26, 2016
Initiation Date
Sep 22, 2016
Termination Date
May 5, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
32,015 bottles

Product description

PARICALCITOL Capsules, 1 mcg, 30-count bottles, Rx only, Manufactured By: Pharmaceutics International, Inc., Hunt Vallet, MD 21031; Manufactured For: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-7656-56.

Reason for recall

Failed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.

Distribution pattern

Nationwide and Puerto Rico

Code information

Lot #: 13013.013A, Exp 04/17

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0109-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0109-2017. Report a data issue: hello@regdatalab.com.